|
|
|
|
||
AND Young left as well back in 2013.https://www.linkedin.com/in/peterryoung Prolific and innovative, as demonstrated by a strong record of publication (120 papers and reviews) and inventorship (31 patents). Demonstrated experience with multiple therapeutic target classes and disease mechanisms, including protein kinases, cytokines, growth factors, cell surface receptors, nuclear receptors and epigenetics. |
return to message board, top of board |